| TITLE |
BODY LOCATION |
DISEASE TYPE |
COORDINATOR |
| A Phase 2b, Multicenter, Randomized, Double-blind, Placebo–controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy (CERTIFI)
|
Large Intestine,Other,
|
Crohns Disease
|
|
|
|
| A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)-Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis
|
Pancreas,
|
Pancreatitis
|
|
|
|
| A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis--Rollover Study
|
Large Intestine,
|
Ulcerative Colitis
|
Rebekah Whichard,
|
| The purpose of this study is to assess the effects (good and bad) of CNTO 148 (golimumab) therapy in patients with ulcerative colitis.
|
| A Study of The Safety and Effictiveness of CNTO 148 (Golimumab) in Patients with Moderately to Severely Active Ulcerative Colitis
|
Large Intestine,
|
Ulcerative Colitis
|
Rebekah Whichard,
|
| The purpose of this clinical study is to assess the effects (good and bad) of CNTO 148 (golimumab) therapy in patients with Ulcerative Colitis.
|
| A Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II)
|
Large Intestine,
|
Crohns Disease
|
Rebekah Whichard,
|
| This multicenter, phase 3, randomized, blinded, placebo-controlled study in patients with moderately to severely active CD comprises two phases:
The Induction Phase, designed to establish the efficacy and safety of vedolizumab (MLN0002) for the induction of clinical response and remission; and the Maintenance Phase, designed to establish the efficacy and safety of vedolizumab(MLN0002) for the maintenance of clinical response and remission.
|
| An Open-Label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease (GEMINI III)
|
Large Intestine,
|
Crohns Disease
|
Rebekah Whichard,
|
| This multicenter, 2-year open-label study will collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
|
| Cimzia Registry
|
Large Intestine,Other,
|
Crohns Disease
|
|
|
|